Similarly, the combination of CTLA-4 inhibitor and chemotherapy increased the risk of pruritus and rash compared with chemotherapy [any grade pruritus RR:6.31 (95%CI 4.40-9.04, p < 0.00001) (Figure 4A); high grade pruritus RR:7.92 (95%CI 1.86-33.66, p = 0.005) (Figure 4B); any grade rash RR:5.32 (95%CI 3.90-7.26, p < 0.00001) (Figure 4C); and high grade rash RR:10.11 (95%CI 2.47–41.41, p = 0.001) (Figure 4D)]. The gene discussed is CTLA4; the disease is Pruritus.